- Types of Eczema
- Child Eczema
- Causes & Triggers
- Living with Eczema
- Eczema Products
- Get Involved
What you need to know Finding a treatment that works for your eczema or atopic dermatitis (AD) symptoms can feel like an endless cycle for some people. And it’s not just about finding the right medicine, but about getting it covered by your health plan as well. It’s hard enough when your eczema is flaring; […]
Understanding AD’s impact to improve your quality of life People living with atopic dermatitis (AD), the most common and chronic form of eczema, know first-hand the burden AD has on both individuals and families. The impacts reach far beyond the serious effects of the disease symptoms such as itch, pain, and inflammation –they also include […]
Eczema affects more than 30 million people in the United States. The most common and chronic form of eczema is known as atopic dermatitis (AD). There is currently no cure for eczema or AD. To help raise awareness about the serious impact AD has on individuals and families, the National Eczema Association (NEA) has joined […]
We asked, you answered. The verdict? People living with eczema want more information and more options. This past January, many of you responded to a 6-question online survey to evaluate patient satisfaction and the role of doctors in the treatment of the most serious form of eczema, atopic dermatitis (AD). We learned that the vast majority of […]
June 9, 2016 – On Monday, June 6, 2016 the pharmaceutical companies Regeneron and Sanofi, reported positive results for the Phase 3 the clinical trial of the new biologic drug, dupilumab, when used in conjunction with a topical corticosteroid by adults to treat moderate-to-severe atopic dermatitis (AD).
February 11, 2016 – Late last month, NEA’s Board of Directors gathered together for the annual NEA Board retreat in San Francisco, California. This year’s retreat focused on both celebrating 2015 successes, and sharing a number of exciting 2016 initiatives that will advance NEA’s Roadmap strategic plan goals.
February 10, 2016 – In January, Anacor Pharmaceuticals, Inc. announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of crisaborole topical ointment, 2%.
November 17, 2016 – This year, more than 450 people joined NEA on two successful Itching for a Cure (IFAC) Walks in Chicago, IL and Los Angeles, CA. Together, we raised nearly $120,000 to improve the quality of life for individuals with eczema through research, support, and education.
September 21 – The National Eczema Association (NEA) has awarded Dr. Aaron Drucker, Assistant Professor, Department of Dermatology at Brown University, with the NEA Burden of Disease Research Audit grant, the findings of which will help to raise the profile of eczema as a serious disease, to deliver stronger, more united messages to insurers, medical providers and policy-makers on behalf of the eczema community.
May 22, 2015 – “Eczema keeps me from doing things that other people enjoy all the time, like going to the beach, riding my bike, going for a walk, and enjoying being outside,” says 13-year-old eczema patient, Isaiah Dixon. But that didn’t stop Isaiah from testifying in March at a Food and Drug Administration (FDA) hearing in Silver Spring, MD, on behalf of the National Eczema Association.